



South Sudan

COUNTRY GENERAL INFORMATION

Total population:	10,606,225
Gender F/M (%):	50.5 / 49.5
Population, age group <15 / ≥ 15 years (%):	46 / 55
Life expectancy at birth (F/M, years):	65 / 61
GDP (PPP int \$):	1 235
Income status:	Low income
Administrative level, number of divisions:	2 nd sub-national administrative level, 80

EPIDEMIOLOGY

	VL	CL	PKDL
Endemicity status:	Endemic	Non endemic	No data
Number of new cases (incidence):	827	No data	12
Number of relapses: ¹	106	No data	N/A
Total number of cases:	933	No data	12
Imported cases (#, %):	0, 0%	No data	N/A
Gender distribution (% F):	45	N/A	No data
Age group distribution (% <5 / 5-14 / >14):	17 / 37 / 46	N/A	No data
Incidence rate (cases/10,000 population in endemic areas):	3.74	No data	N/A
Number of endemic 2 nd sub-national administrative level divisions:	23	No data	N/A
Population at risk (% & # at risk / total population): ²	21% 2,212,238 / 10,606,225	0% 0 / 10,606,225	N/A
Was there any outbreak?	No	No data	N/A
Number of new foci: ³	No data	No data	N/A


Monthly distribution of new cases (January-December)

2020	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	152	61	119	78	42	59	41	44	59	65	62	45

N/A not applicable; VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis



Number of new cases and Incidence rate/10,000 at the national level from 2005 to 2020




¹Relapse in this country is defined as: "A patient who returns with VL symptoms and has a positive parasitological test after having successfully been treated with antileishmanial medicines and discharged"

²Defined as "Number of people living in 2nd sub-national administrative level endemic areas"

³Defined as "In this reporting period, an area at the 2nd sub-national administrative level reporting cases for the first time ever"

Disease distribution of new VL cases at 2nd sub-national administrative level per 10,000 population (2020)



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
Map production: WHO/UCN/NTD

CONTROL AND SURVEILLANCE⁴

Year Leishmaniasis National Control Programme (LNCP) was established:	No data
Type of surveillance (CL / VL):	N/A / Vertical
Is there a vector control programme?	No data
Type of insecticide used for Indoor residual Spraying (IRS):	No data
Year latest national guidelines (CL / VL):	N/A / 2011
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	N/A / No
Is there a reservoir host control programme?	No data
Number of leishmaniasis health facilities (CL / VL):	N/A / 27

DIAGNOSIS FOR NEW CASES

	VL	CL	PKDL
Number of people screened actively for:	No data	N/A	N/A
Number of people screened passively for:	No data	No data	N/A
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	No data	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	No data	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / new cases):	No data	No data	N/A
Proportion of positive slides (% , # slides + / total slides):	No data	No data	N/A
Cases diagnosed clinically (% , # clinical cases / new cases):	No data	No data	N/A
Percentage of cases with HIV-VL coinfection:	1% (11/933)	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

TREATMENT AND MEDICINES

- Is treatment provided for free in the public sector? (CL / VL): N/A / No data
Amphotericin B deoxycholate, Liposomal amphotericin B, Meglumine antimoniate, Miltefosine, Paromomycin, Sodium stibogluconate (SSG)
- Antileishmanial medicines included in the National Medicine List:

INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	CL
Cases that completed treatment (% , # completed treatment / new cases):	68% (565/827)	No data
Initial cure rate (% , # cases initially cured / new cases):	No data	No data
Failure rate (% , # cases with treatment failure / new cases): ⁵	No data	No data
Case fatality rate (% , # cases who died / new cases):	No data	No data

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis

⁴Data from 2018

⁵Failure in this country is defined as: "A VL patient who has failed to respond despite taking adequate and appropriate treatment"